2001 Fiscal Year Final Research Report Summary
Gene therapy for the liver metastasis of the pancreatic cancer using p53 adenovirus vector
| Project/Area Number |
12671225
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
KITAGAWA Toru Osaka University, Graduate School of Medicine, Assistant Professor, 医学系研究科, 助手 (40314322)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NISHIDA Toshiro Osaka University, Graduate School of Medicine, Assistant Professor, 医学系研究科, 助手 (40263264)
|
|---|
| Project Period (FY) |
2000 – 2001
|
| Keywords | Pancreatic cancer / Liver metastasis / Gene therapy / p53 / Adenovirus vector |
|---|
| Research Abstract |
Prognosis of the pancreatic cancer, even if it is resectable, is extremely poor because of the local recurrence or the liver metastasis. Although extended pancreatectomy and intraoperative radiotherapy are effective to the control of the local recurrence, chemotherapy or other conventional therapies are not effective to the liver metastasis. A new therapy including a gene therapy is expected for the treatment of the pancreatic cancer.
The purpose of this study is to evaluate the usefulness of intraportal administration of p53 adenovirus vector for the liver metastases of the pancreatic cancer.
As a result, intraportal administration of p53 adenovirus vector showed antitumor effect to the murine liver metastasis models using tumor cell lines with p53 mutation. Repeated administration of p53 adenovirus vector could enhance the antitumor effect in murine liver metastasis models. On the other hand, using tumor cell lines without p53 mutation, we could not confirm the antitumor effect of intraportal administration of p53 adenovirus vector in the murine liver metastasis models. In additions, any side effect of intraportal administration of p53 adenovirus vector has not been observed in our murine experiments.
With the aim of clinical application of cancer gene therapy to the liver metastasis, we have also examined the intraportal administration of IL-12 transduced fibroblast cells. The antitumor effect to the liver metastasis and the induction of antitumor immunity were confirmed using similar marine liver metastasis models. It is expected that the clinical application of cancer gene therapy would improve the prognosis of the liver metastasis and the quality of life in cancer patients.
|
